SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Reaman GH. Pediatric cancer research from past successes through collaboration to future transdisciplinary research. J Pediatr Oncol Nurs. 2004; 21: 123127.
  • 2
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166178.
  • 3
    Gurney J, Bondy M. Epidemiology of childhood cancer. In: PizzoPA, PoplackDG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott-Williams & Wilkins; 2006: 113.
  • 4
    Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: PizzoPA, PoplackDG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott-Williams & Wilkins; 2006: 538590.
  • 5
    Meacham LR, Gurney JG, Mertens AC, et al. Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. Cancer. 2005; 103: 17301739.
  • 6
    Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005; 45: 881891.
  • 7
    Ross JA, Oeffinger KC, Davies SM, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2004; 22: 35583562.
  • 8
    Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003; 21: 13591365.
  • 9
    Sklar CA, Mertens AC, Walter A, et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000; 35: 9195.
  • 10
    Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001; 19: 31633172.
  • 11
    Oeffinger KC, Buchanan GR, Eshelman DA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001; 23: 424430.
  • 12
    Ness KK, Oakes JM, Punyko JA, Baker KS, Gurney JG. Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol. 2005; 15: 202206.
  • 13
    Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004; 89: 50035012.
  • 14
    Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev. 2002; 28: 195214.
  • 15
    Talvensaari K, Knip M. Childhood cancer and later development of the metabolic syndrome. Ann Med. 1997; 29: 353355.
  • 16
    Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996; 81: 30513055.
  • 17
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation. 2005; 112: e285290.
  • 18
    Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2004: 118145.
  • 19
    Bulow B, Link K, Ahren B, Nilsson AS, Erfurth EM. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf). 2004; 61: 683691.
  • 20
    Ham JN, Ginsberg JP, Hendell CD, Moshang TJr. Growth hormone releasing hormone plus arginine stimulation testing in young adults treated in childhood with cranio-spinal radiation therapy. Clin Endocrinol (Oxf). 2005; 62: 628632.
  • 21
    Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003; 88: 95102.
  • 22
    Cohen LE. Endocrine late effects of cancer treatment. Curr Opin Pediatr. 2003; 15: 39.
  • 23
    McCallum RW, Petrie JR, Dominiczak AF, Connell JM. Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf). 2002; 57: 1124.
  • 24
    Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993; 129: 195200.
  • 25
    Flint DJ, Gardner MJ. Influence of growth hormone deficiency on growth and body composition in rats: site-specific effects upon adipose tissue development. J Endocrinol. 1993; 137: 203211.
  • 26
    Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol. 2005; 153: 8189.
  • 27
    Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab. 2005; 90: 14661474.
  • 28
    Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab. 2002; 87: 36503655.
  • 29
    Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 1997; 82: 28772884.
  • 30
    Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002; 38: 229239.
  • 31
    Dominici R, Luraschi P, Franzini C. Measurement of C-reactive protein: two high sensitivity methods compared. J Clin Lab Anal. 2004; 18: 280284.
  • 32
    Gonzalez-Sagrado M, Martin-Gil FJ. Population-specific reference values for thyroid hormones on the Abbott ARCHITECT i2000 analyzer. Clin Chem Lab Med. 2004; 42: 540542.
  • 33
    Stauffenberg MT, Lange RA, Hillis LD, et al. Hyperhomocysteinemia measured by immunoassay: a valid measure of coronary artery atherosclerosis. Arch Pathol Lab Med. 2004; 128: 12631266.
  • 34
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412419.
  • 35
    Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002; 87: 20672079.
  • 36
    Ghigo E, Aimaretti G, Arvat E, Camanni F. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 2001; 15: 2938.
  • 37
    Jarfelt M, Bjarnason R, Lannering B. Young adult survivors of childhood acute lymphoblastic leukemia: spontaneous GH secretion in relation to CNS radiation. Pediatr Blood Cancer. 2004; 42: 582588.
  • 38
    Ascaso JF, Romero P, Real JT, et al. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med. 2003; 14: 101106.
  • 39
    Wahrenberg H, Hertel K, Leijonhufvud BM, Persson LG, Toft E, Arner P. Use of waist circumference to predict insulin resistance: retrospective study. BMJ. 2005; 330: 13631364.
  • 40
    Colao A, Cerbone G, Pivonello R, et al. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab. 1999; 84: 12771282.
  • 41
    Hoffman AR. Treatment of the adult growth hormone deficiency syndrome: directions for future research. Growth Horm IGF Res. 2005; 15( Suppl A): 4852.
  • 42
    Rosen T, Johannsson G, Johansson JO, Bengtsson BA. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper. Horm Res. 1995; 43: 9399.
  • 43
    Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004; 89: 33063312.
  • 44
    Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab. 1996; 81: 555564.
  • 45
    Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab. 2005; 16: 190197.
  • 46
    Sklar CA. Growth hormone treatment: cancer risk. Horm Res. 2004; 62 Suppl 3: 3034.
  • 47
    Bjork J, Link K, Erfurth EM. The utility of the growth hormone (GH) releasing hormone-arginine test for diagnosing GH deficiency in adults with childhood acute lymphoblastic leukemia treated with cranial irradiation. J Clin Endocrinol Metab. 2005; 90: 60486054.